zero, and 2-4 concomitant vaccines, respectively. About 49% of the reports indicated that patients were on concurrent medications at the time of vaccination, yet; only 12% of the reports stated that the patients were having coexisting illnesses at vaccination time. Compared to other vaccines, FLU and MNQ vaccines showed significantly higher PRR values (10.5, 95%CI 9.4-11.8), (4.7, 95%CI 3.4-6.6). CONCLUSIONS: It can be postulated that some vaccines are associated with GBS, especially FLU and MNQ vaccines; underscoring the importance of monitoring patients for postvaccination signs and symptoms of GBS. While healthcare professionals are expected to promote vaccination, they should also continue to report vaccine-associated adverse events to vaccine safety monitoring systems, e.g. VAERS.
OBJECTIVES: MRSA skin infections are associated with high morbidity and cost. Little is known about real-world daptomycin effectiveness in relevant subpopulations. We evaluated outcomes including time to response, duration of antibiotic therapy, and antibiotic-related hospital length of stay (AR-LOS) in subpopulations of patients with MRSA skin infections treated with daptomycin. METHODS: Patients with MRSA skin infections were identified in a retrospective, multicenter, observational registry describing safety and real-world effectiveness of patients treated with daptomycin (Cubicin Outcomes Registry and Experience; CORE®). Investigators assessed patient outcome at the end of daptomycin therapy. Subpopulations of interest included those with reduced vancomycin susceptibility (MIC Ն2mcg/mL), the elderly, diabetics, and those with renal dysfunction. RESULTS: A total of 137 patients were identified: 53% male, 33% Ͼ65yo, 31% diabetic, 6% CrCL Ͻ30ml/min. Of patients with vancomycin MICs, 14% were Ͼ2. Median daptomycin dose was 6mg/kg; 82% had prior antibiotics (66% of which was vancomycin). Success occurred in 94% overall, and was 100% in first-line daptomycin, 93% as second line. Time to clinical response ranged from 2-4 days with a median of 3 days for both first and second-line therapy. Median AR-LOS tended to be greater among subpopulations: those with vancomycin MIC Ն2 [5 vs. 4 days], Ͼ65 yo [6 vs. 5 days], diabetics [6 vs. 4 days], and those with CrCL Ͻ30 [8 vs. 5 days], compared to those without each respective condition. Total treatment duration (inpatient and outpatient days) ranged from 7-13 days, depending on clinical subgroup. 11/137 patients (8.3%) had AEs possibly related to daptomycin; discontinuation due to AE was 5.8%. CONCLUSIONS: This evaluation of relevant patient populations provides meaningful information about real-world effectiveness of daptomycin-treated MRSA skin infections. AR-LOS was longer in evaluated subgroups, particularly those with CrCL Ͻ30ml/min. Additional real-world evaluations, including comparative effectiveness studies are warranted to further evaluate relevant outcomes in various subpopulations with MRSA skin infections.
PIN3 A META-ANALYSIS OF EFFICACY AND SAFETY OF LINEZOLID FOR INFECTED DIABETIC FOOT TREATMENT
Villasis-Keever MA 1 , Rendon-Macias M 1 , Esacamilla-Nuñez A 1 , Mould-Quevedo J 2 , Muciño-Ortega E 3 , Galindo-Suarez RM 3 1 Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico, 2 Pfizer, New York, NY, USA, 3 Pfizer, Mexico OBJECTIVES: In diabetes mellitus patients, infected diabetic foot represents 20% of hospitalizations. In order to minimize health services cost its important to evaluate which antimicrobial agent could be the best option. The aim of this study was to conduct a meta-analysis of randomized clinical trials (RCTs) to determine effectiveness and safety of linezolid in the treatment of infected diabetic foot in comparison with other antimicrobial agents. METHODS: All meta-analysis estimations were performed with RCTs based on trials enrolling patients with mild to moderate diabetic foot infections treated with one antimicrobial agent. Effectiveness was assessed through clinical efficacy (cure/healing); safety and microbiological endpoint indicators. RCTs were searched in December 2009 in Medline, EMBASE, and the Cochrane Collaboration. Two independent reviewers identified abstracts, selected full articles, and extracted the data. Odds ratios (OR) and weighted mean differences were calculated. Random effects models were employed in the analyses with RevMan v.5.0 software. RESULTS: 1,528 studies were reviewed and 19 trials were finally selected. 13/19 RCTs assessed patients with diabetes mellitus and 6/19 patients with soft tissue infections. Regarding clinical results: linezolid was as effective as ciproflaxin, ofloxacin and ertapenem; although with higher clinical efficacy compared to piperacillin/tazobactam (OR 0.52; IC95% 0.34Ϫ0.77 pϭ0.001), ampicillin/sulbactam (OR 0.40; CI95% 0.27Ϫ0.61 pϽ0.001) and daptomicin (OR 0.45; IC95% 0.22-0.90 pϭ0.02). Regarding microbiological efficacy, similar results were estimated (Staph. aureus eradication); however, ertapenem showed a better result (OR 2.60; CI95% 1.11-6.07 pϭ0.03) than linezolid. Nevertheless, linezolid exhibited superiority against oxiflacin (OR 0.36; CI95% 0.20-0.65, pϭ0.0006). Frequency of adverse events was similar in all RCTs. CONCLUSIONS: Currently, little published evidence exists to define which antimicrobial agent would be the optimum drug for mild to moderate infected diabetic foot patients. Though, linezolid demonstrated to be an effective and safe treatment using clinical and microbiological endpoints.
PIN4 EFFICACY AND SAFETY OF THE COMBINATION EFAVIRENZ (EFV), TENOFOVIR (TDF) AND EMTRICITABINE (FTC) ONCE A DAY IN TREATMENT OF NAÏVE ADULT PATIENTS WITH HIV-1 INFECTION: A SYSTEMATIC REVIEW
Rizzoli-Cordoba A 1 , Delgado-Ginebra I 2 1 Hospital Infantil de México Federico Gómez, Mexico City, Mexico, 2 Panamerican University, Mexico OBJECTIVES: In patients with HIV-1, the reduction in RNA copies associated to treatment has shown a better survival rate. The Highly Active Antiretroviral Therapy (HAART) is the recommended treatment for those patients. As a chronic disease, the adherence to treatment and adverse effects plays a mayor role. The objective was to evaluate the efficacy and safety of the combination Efavirenz, Tenofovir and Emtricitabine (EFV/TDF/FTC) administred once daily compared to the available treatment combinations in Mexico. METHODS: We conducted a systematic review using the Cochrane guidelines of randomized clinical trials in PubMed, EMBASE, LILACS AND Artemisa to compare EFV/TDF/FTC, TDF/ FTCϩATV/r, TDF/FTCϩLPV/r, TDF/FTCϩSQV/r, TDF/FTCϩFPV/r, ABC/3TCϩEFV, ABC/3TCϩLPV/r, ZDV/3TC/EFV, ZDV/3TCϩLPV/r in naïve adult patients with HIV-1 infection. The main outcome variables were RNA HIV-1 copies less than 50/mm 3 at 48 and 96 weeks, and grade 2-4 adverse effects at 48 weeks. We used a random model effects for the pooled analysis. RESULTS: We included 13 articles, 9 at 48 weeks and 4 at 96 weeks. The arms were grouped by the three elements of HAART. The combination EFV/TDF/FTC was the most frequently used (4 and 2 studies at 48 and 96 weeks). At 48 and 96 weeks the pooled probabilities to have Ͻ50 RNA copies/ml for EFV/TDF/FTC were 0.784 (CI95%:0.736-0.825; nϭ962) and 0.734 (0.601-0.835; nϭ514); TDF/FTCϩLPV/r 0.694(0.611-0.766; nϭ958) and 0.633(0.528-0.726; nϭ788); TDF/FTCϩATV/r 0.848(0.652-0.943; nϭ488) and 0.743(0.700-0.782; nϭ440) respectively. The 2-4 grade adverse events rates at 48 weeks were for EFV/ TDF/FTC 0.225(0.074-0.513; nϭ1129); for ABC/3TCϩEFV 0.316(0.279-0.354; nϭ589); and for ZDV/3TC/EFV 0.634(0.573-0.691; nϭ254). At 48 weeks the discontinuation rate for EFV/TDF/FTC was 0.051(nϭ536); TDF/FTCϩLPV/r 0.071(nϭ170); and for ZDV/3TCϩEFV 0.079(nϭ349); the lowest was TDF/FTCϩSQV 0.028(nϭ176). CONCLUSIONS: The combination EFV/TDF/FTC is the most studied combination and is clinically effective at 48 and 96 weeks, with good safety profile. The administration once a day improves the adherence to treatment. 
PIN5 THE PREVALENCE AND ECONOMIC BURDEN OF HEPATITIS C VIRUS INFECTION IN CANADA AND LATIN AMERICA: A SYSTEMATIC REVIEW

OBJECTIVES:
The global prevalence of hepatitis C virus (HCV) infection is estimated at over 300 million persons. Despite stable prevalence, the economic burden in the United States (US) is projected to double over the next decade. Less is known, however, for the rest of the Americas. These epidemiologic and economic data are critical for decision-makers to project the impacts of HCV treatments. The objective of this study was to synthesize literature-based estimates of the prevalence and economic burden of HCV from Canada, Mexico, Brazil, Argentina, Peru, Colombia, and Venezuela. METHODS: A systematic review was conducted in September 2010 to determine the a) prevalence, and b) resultant economic burden, of HCV. Two independent reviewers extracted data from articles meeting the inclusion criteria: from EMBASE, Medline, or the Cochrane databases; focusing on general population estimates from the target countries; and published since the year 2000.
RESULTS:
The search strategy identified 280 abstracts; eight provided general population prevalence estimates. In Brazil, the prevalence was estimated at 1.4% in Sao Paulo, and 3.6% in the state of Para. Canadian national surveillance programs estimated HCV prevalence at 0.8%; with provincial estimates from 1.3% to 2.0%. Mexican estimates ranged from 0.7% to 2.0%; the national health survey reported a prevalence of 1.4%. No prevalence estimates were identified for the remaining countries. Only one study (from Canada) assessed the overall economic burden. Despite a predicted 14% decrease in prevalence, HCV-related costs were projected to increase by over 50%, to 158 million dollars annually by 2040. CONCLUSIONS: HCV prevalence estimates varied from 0.8% to 3.6%, from general population based studies from Canada, Mexico, and Brazil. Canadian data suggest the economic burden of HCV is large, and increasing. While these data are useful for decisionmakers, the paucity of data for South America highlights a substantial knowledge gap.
PIN6
TRENDS OF HEPATITIS A INCIDENCE FROM 2005 TO 2008
Eisenberg D 1 , Changolkar AK 2 , Misurski DA 2 1 HealthCore, Inc., Wilmington, DE, USA, 2 GlaxoSmithKline, Philadelphia, PA, USA In 1996 the US Advisory Committee on Immunization Practices recommended administration of hepatitis A vaccine for those at risk of infection. In 2005, the recommendation was extended to all children and at risk adults. Comprehensive data on hepatitis A incidence in a managed care population has not been evaluated. OBJECTIVES: To evaluate the incidence of hepatitis A in a managed care population from 2005 to 2008. METHODS: This was an observational, retrospective cohort study utilizing medical and pharmacy claims data from January 1, 2005 through December 31, 2008 from the HealthCore Integrated Research Database (HIRD SM ). The index date was defined as date of first diagnostic claim for hepatitis A within the intake period. Patients included were at least 18 years old and had continuous eligibility for at least 12 months prior to and after index date. RESULTS: A total of 7674 patients were diagnosed with hepatitis A (51.1% male). Annual incidence was similar for A114 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 -A 2 1 4
